EOLS Stock — Evolus Inc.: Cash, EV, Pipeline

Share price

$7.86

Market cap

$519.2M

Cash

$45.2M

Enterprise value

$630.8M

Balance sheet

Cash	$45.2M
Debt	$156.7M
Net cash	-$111.6M
Enterprise value	$630.8M
Basic shares	66.0M shares
Fully diluted shares	81.1M shares
Fully diluted market cap	$637.7M
Cash per share	$0.68

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading EOLS daily closes…

Loading price history…

Pipeline assets

Jeuveau

Approved · Active Modality: Injectable (botulinum toxin)

Aliases prabotulinumtoxinA-xvfs, Nuceiva (Canada/Europe/Australia)

Partnerships Daewoong: license agreement (manufacture/supply); Medytox: settlement agreements governing rights to market/sell Jeuveau

Indications

Facial aesthetics (glabellar lines) (Approved)

Status note Approved aesthetic neurotoxin; marketed in US, Canada, Europe, Australia. Company depends on Daewoong/Medytox/Symatese agreements for supply and distribution rights.

Evolysse

Approved · Active Modality: Injectable hyaluronic acid (HA) gel

Aliases Estyme (ex-US), Evolysse Form, Evolysse Smooth

Partnerships Symatese: exclusive US rights (Apr 2025 launch of Evolysse Form/Smooth; Lips/Eye products in US registration; cost-sharing on FDA registration) + exclusive rights in 50 European countries (four products launched May 2026; MDR approval Oct 2024); milestone payments (up to ~16.2M EUR US + EUR 1.2M/1.9M EU) + royalties; Symatese is sole supplier

Indications

Aesthetic/dermatological dermal filler (Approved)

Status note Injectable HA gel dermal filler line; FDA-approved products launched US Apr 2025, EU May 2026. Lips and Eye products under US registration.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06903975	Not disclosed	Recruiting	Collaborator	Boston Medical Center	—	Neck Muscle Issue	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Boston Medical Center on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	3,155,209	+50,000	0.81%	2026-08-14
Frazier Life Sciences	2,630,665	no change	0.40%	2026-08-14
ADAR1 Capital Management	100,000	+44,141	0.03%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

EOLS — Evolus Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials

Institutional holders